|
Session 106-Poster Abstracts
ART Strategies and Predictors of Response
Tuesday, 2-4 pm; Hall A |
533
 |
Baseline HIV RNA Ultrasensitive Assay and Viral DNA Predict Rise in Plasma Viral Load in Patients of MONOI-ANRS 136 Trial
Anne-Geneviève Marcelin*1,2, S Lambert-Niclot1,2, G Peytavin3, C Duvivier4, M Algarte-Genin1, Y Yazdanpanah5, P-M Girard6, C Katlama1,2, V Calvez1,2, and P Flandre1,2
1INSERM U943, Paris, France; 2Univ Pierre and Marie Curie, Hosp Pitie-Salpetriere, Paris, France; 3Hosp Bichat Claude Bernard, Univ Paris 7, France; 4Inst Pasteur and Hosp Necker, Univ Paris Descartes, France; 5Hosp Tourcoing, France; and 6Hosp St Antoine, Paris, France |
534
|
Long-term Efficacy of DVR/r Monotherapy in Patients with HIV-1 Viral Suppression in the MONOI-ANRS 136 Study: Results at 96 Weeks
Marc-Antoine Valantin*1,2, C Duvivier3,4, S Lambert-Niclot1, P Flandre2, A Cabié5, J-M Molina6, L Cuzin7, L Slama8, A-G Marcelin1, and C Katlama1
1Hosp Pitie-Salpetriere, Paris, France; 2INSERM U943, Paris, France; 3Hosp Necker, Paris, France; 4Inst Pasteur Med Ctr, Paris, France; 5Hosp Fort-de-France, Martinique, France; 6Hosp St Louis, Paris, France; 7Hosp Purpan, Toulouse, France; and 8Hosp Tenon, Paris, France |
535
|
Association of Baseline Viral Load, CD4 Count, and Week 4 Virologic Response with Virologic Failure in ACTG Study A5202
Philip Grant*1, C Tierney2, D Katzenstein1, P Sax3, C Budhathoki2, K Mollan2, A Collier4, M Fischl5, A Zolopa1, E Daar6, and ACTG Study A5202
1Stanford Univ, CA, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Brigham and Women`s Hosp and Harvard Med Sch, Boston, MA, US; 4Univ of Washington and Harborview Med Ctr, Seattle, US; 5Univ of Miami Miller Sch of Med, FL, US; and 6Univ of California, Los Angeles, US |
| 536 |
Association of Race/Ethnicity and Sex on Outcomes in ACTG Study A5202
Kimberly Smith*1, C Tierney2, E Daar3, K Mollan2, C Budhathoki2, P Sax4, D Katzenstein5, C Godfrey6, M Fischl7, A Collier8, and ACTG A5202 Study Team
1Rush Univ Med Ctr, Chicago, IL, US; 2Statistical Data Analysis Ctr, Harvard Sch of Publ Hlth, Boston, MA, US; 3Univ of California, Los Angeles Med Ctr, US; 4Brigham and Women`s Hosp, Harvard Med Sch, Boston, MA, US; 5Stanford Univ, Palo Alto, CA, US; 6DAIDS, NIAID, NIH, Bethesda, MD, US; 7Univ of Miami Miller Sch of Med, FL, US; and 8Univ of Washington and Harborview Med Ctr, Seattle, US |
| 537 |
Efficacy and Safety of Generic NVP-based First-line ART in China, a Prospective Randomized Multicenter 100-week Study
Wei Lu*, Y Han, F Guo, and T Li
Peking Union Med Coll Hosp, Beijing, China |
538
|
ZDV/3TC vs d4T/3TC Outcomes among HIV-1-infected Adults Receiving First-line Combination ART in Botswana: Results from a Clinical Trial
William Wester*1,2, M Blevins1, H Bussmann2,3, S Moyo3, M Farahani2, B Shepherd1, J Makhema3, M Essex2,3, V deGruttola2, and R Marlink2,3
1Vanderbilt Univ Sch of Med, Nashville, TN, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; and 3Botswana-Harvard AIDS Inst Partnership, Gaborone |
539
|
Predictors of Suboptimal CD4 Response among Women Achieving Virologic Suppression in a Randomized ART Trial, Africa
A Asmelash1, Y Zheng2, K Wools-Kaloustian3, D Shaffer4, F Sawe4, R Salata5, E Stringer6, J Currier7, M Hughes2, and Shahin Lockman*2,8
1Botswana-Harvard AIDS Inst Partnership, Gaborone; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Indiana Univ Sch of Med, Indianapolis, US; 4The Walter Reed Project, Kericho, Kenya; 5Case Western Reserve Univ, Cleveland, OH, US; 6Ctr for Infectious Disease Res, Lusaka, Zambia; 7Univ of California, Los Angeles, US; and 8Brigham and Women`s Hosp, Boston, MA, US |
| 540 |
Low CD4 Count on Effective HAART Is Associated with Immunologic and Vascular Dysfunction
Hiroyu Hatano*1, P Hsue1, P Hunt1, J Martin1, T-H Lee2, E Sinclair1, M Busch1,2, and S Deeks1
1Univ of California, San Francisco, US and 2Blood Systems Res Inst, San Francisco, CA, US |
| 541 |
Second-line Boosted Protease-containing Therapy: Assessing the Impact of Maintaining 3TC vs Switching to ddI in Addition to 2 Drugs from New Classes in a Randomized Comparison
Ivan Mambule*1, S Walker2, A Reid3, F Ssali4, P Munderi5, H Grosskurth5, D Gibb2, J Hakim3, P Mugyenyi4, C Gilks6, and DART Trial Team
1Infectious Disease Inst, Kampala, Uganda; 2MRC Clin Trials Unit, London, UK; 3Univ of Zimbabwe Clin Res Ctr, Harare; 4Joint Clin Res Ctr, Kampala, Uganda; 5MRC/Uganda Virus Res Inst, Entebbe; and 6Imperial Coll London, UK |
542
|
RAL Demonstrates Durable Virologic Suppression and Superior Immunologic Response with a Favorable Metabolic Profile through 3 Years of Treatment: 156-Week Results from STARTMRK
Jürgen Rockstroh*1, J Lennox2, E DeJesus3, M Saag4, A Lazzarin5, X Xu6, H Teppler6, B-Y Nguyen6, R Leavitt6, P Sklar6, and STARTMRK Study Team
1Univ of Bonn, Bonn-Venusberg, Germany; 2Emory Univ, Atlanta, GA, US; 3Orlando Immunology Ctr, FL, US; 4Univ of Alabama at Birmingham, US; 5Univ Vita-Salute San Raffaele, Milan, Italy; and 6Merck Res Labs, North Wales, PA, US |
543
|
DAART Is Superior to Self-administered Therapy among Released HIV+ Prisoners: Results from a Randomized Controlled Trial
Frederick Altice*, A Saber-Tehrani, J Qiu, M Herme, and S Springer
Yale Univ, New Haven, CT, US |
| 544 |
Directly Observed Weekly Fluoxetine Improves Unannounced Pill Count Antiretroviral Adherence and Mood in HIV+ Depressed, Homeless/Marginally Housed Individuals
David Bangsberg*1,2, A Tsai2, D Karasic3, G Hammer3, E Charlebois3, K Ragland3, A Moss3, J Sorensen3, and J Dilley3
1Massachusetts Gen Hosp, Boston, US; 2Harvard Univ, Boston, MA, US; and 3Univ of California, San Francisco, US |
545
|
Effect of RAL Intensification in HAART-suppressed Subjects without Proper CD4 T Cell Recovery
Marta Massanella*1, M Buzon1, J Puig2, N Pérez-Álvarez2,3, M Puertas1, J Martinez-Picado1,4, B Clotet1,2, J Blanco1, E Negredo2, and DISCOR-RAL Collaborative Group
1Fndn irsiCaixa, Badalona, Spain; 2Fndn Lluita contra la SIDA, Badalona, Spain; 3Tech Univ of Catalonia, Barcelona, Spain; and 4Inst Catalana de Recerca i Estudis Avancats, Barcelona, Spain |
546
|
Recurring Interruption of ART Results in Loss of Protective Humoral Immunity to Neo-antigens in HIV-infected Individuals
Livio Azzoni*1, A Foulkes2, C Firnhaber3, X Yin1, Z Xiang1, Y Li1, W Stevens3, H Ertl1, I Sanne3, and L Montaner1
1The Wistar Inst, Philadelphia, PA, US; 2Univ of Massachusetts, Amherst, US; and 3Univ of the Witwatersrand, Johannesburg, South Africa |
547
|
Immunological Effects of Treatment Intensification with MVC in Recently Infected HIV-1-naive Subjects Starting RAL + TDF/FTC: The Maraviboost Study
Marta Massanella*1, J Llibre2, M Puertas1, N Pérez-Álvarez2, J Miro3, J Martinez-Picado1,4, B Clotet1,2, J Blanco1, and Maraviboost Study Group
1Fndn irsiCaixa, Badalona, Spain; 2Fndn Lluita contra la SIDA, Badalona, Spain; 3Hosp Clin, Univ of Barcelona, Spain; and 4Inst Catalana de Recerca i Estudis Avancats, Barcelona, Spain |
|
